NDAORALTABLET
Approved
Jul 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Codeine sulfate is an oral tablet small-molecule opioid agonist approved in 2009 for mild to moderate pain where alternative treatments are inadequate. It binds weakly to mu-opioid receptors with analgesic properties speculated to derive from conversion to morphine, though the exact mechanism remains unknown.
$0.241MPart D
LOE ApproachingLimited commercial opportunity as product approaches loss of exclusivity with minimal market claims relative to competitors.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Codeine sulfate offers limited career advancement opportunities given its LOE-approaching lifecycle and minimal linked job openings. Roles focus on defensive commercial management and operational efficiency rather than growth or innovation.
Generic Product ManagerField Sales Representative
Worked on CODEINE SULFATE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.